This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

9 Meters Biopharma Management

Management Kriterienprüfungen 0/4

Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.

Wichtige Informationen

Bethany Sensenig

Geschäftsführender

US$1.3m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	35.7%
Amtszeit als Geschäftsführer	1.5yrs
Eigentum des Geschäftsführers	0.2%
Durchschnittliche Amtszeit des Managements	keine Daten
Durchschnittliche Amtszeit der Vorstandsmitglieder	2.9yrs

Jüngste Management Updates

Recent updates

9 Meters Biopharma to execute 1-for-20 reverse stock split

Oct 17

9 Meters Biopharma GAAP EPS of -$0.04 in-line

Aug 15

9 meters launches Phase 2 VIBRANT study of vurolenatide for short bowel syndrome

Jun 14

9 Meters drug effective in treating rare COVID-19 complication in children

May 26

9 Meters Bio gains 5% on Adage Capital stake disclosure

Dec 29

9 Meters Biopharma slumps, continues evaluation of Larazotide for COVID-19 respiratory complications

Dec 21

9 Meters Bio launches equity offering

Dec 11

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Bethany Sensenig im Vergleich zu den Einnahmen von 9 Meters Biopharma verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Mar 31 2023	n/a	n/a	-US$46m
Dec 31 2022	US$1m	US$457k	-US$44m

Vergütung im Vergleich zum Markt: BethanyDie Gesamtvergütung ($USD1.28M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt US ($USD647.72K).

Entschädigung vs. Einkommen: Unzureichende Daten, um die Vergütung von Bethany mit der Unternehmensleistung zu vergleichen.

Geschäftsführer

Bethany Sensenig (47 yo)

1.5yrs

Amtszeit

US$1,279,586

Vergütung

Ms. Bethany Sensenig MBA, CMA, serves as Interim Chief Executive Officer of 9 Meters Biopharma, Inc. since May 30, 2023. She serves as a Chief Financial Officer at 9 Meters Biopharma, Inc. since January 15...

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Lorin Johnson	Independent Director	5.5yrs	US$84.70k	0.057% $ 1.6k
Mark Sirgo	Independent Chairman	3.3yrs	US$119.70k	0.57% $ 16.2k
Mark Pimentel	Member of Scientific Advisory Board	2.9yrs	keine Daten	keine Daten
Michael Rice	Independent Director	2.4yrs	US$78.45k	0.027% $ 768.9
Michael Constantino	Independent Director	3.1yrs	US$82.20k	0.048% $ 1.4k
Z. Falchuk	Member of Scientific Advisory Board	2.9yrs	keine Daten	keine Daten
Maureen Leonard	Member of Scientific Advisory Board	2.9yrs	keine Daten	keine Daten
Russel Cohen	Member of Scientific Advisory Board	2.9yrs	keine Daten	keine Daten
Benjamin Lebwohl	Member of Scientific Advisory Board	2.9yrs	keine Daten	keine Daten
Charles Randall	Member of Scientific Advisory Board	2.9yrs	keine Daten	keine Daten
Samantha Ventimiglia	Independent Director	1.8yrs	US$67.20k	0.027% $ 768.9

2.9yrs

Durchschnittliche Betriebszugehörigkeit

60yo

Durchschnittliches Alter

Erfahrener Vorstand: NMTRDie Vorstandsmitglieder gelten nicht als erfahren ( 2.9 Jahre durchschnittliche Amtszeit), was auf einen neuen Vorstand hindeutet.

This company listing is no longer active

9 Meters Biopharma Management

Management Kriterienprüfungen 0/4

Wichtige Informationen

Jüngste Management Updates

9 Meters Biopharma, Inc. Appoints Bethany Sensenig as Interim CEO

High number of new and inexperienced directors

Independent Chairman recently bought US$50k worth of stock

9 Meters Biopharma, Inc., Annual General Meeting, Jun 22, 2022

High number of new and inexperienced directors

President recently bought US$56k worth of stock

Recent updates

9 Meters Biopharma Receives Notice from Nasdaq Regarding Non-Compliance with Minimum Bid Price Rule

9 Meters Biopharma, Inc. Appoints Bethany Sensenig as Interim CEO

9 Meters Biopharma, Inc. Provides Clinical Update on Vurolenatide in Patients with Short Bowel Syndrome

Price target decreased by 43% to US$10.25

Consensus EPS estimates fall by 43%

Price target decreased by 32% to US$22.68

Price target increased by 18% to US$39.20

Price target decreased by 15% to US$33.12

9 Meters Biopharma, Inc. Announces Phase 3 Study of Vurolenatide in Short Bowel Syndrome

High number of new and inexperienced directors

Price target decreased to US$57.00

9 Meters Biopharma to execute 1-for-20 reverse stock split

Price target increased to US$3.40

9 Meters Biopharma Announces Positive Final Results from Phase 2 VIBRANT Study and Successful End-of-Phase 2 Meeting with FDA for Vurolenatide in Short Bowel Syndrome

9 Meters Biopharma GAAP EPS of -$0.04 in-line

9 Meters Biopharma Announces Positive Preliminary Results from Phase 2 Study of Vurolenatide in Short Bowel Syndrome

9 Meters Biopharma, Inc. announced that it expects to receive $70 million in funding

Price target decreased to US$3.33

Independent Chairman recently bought US$50k worth of stock

9 Meters Biopharma, Inc., Annual General Meeting, Jun 22, 2022

High number of new and inexperienced directors

President recently bought US$56k worth of stock

9 Meters Biopharma Provides Clinical Update on Late-Stage Pipeline Products Vurolenatide for Short Bowel Syndrome and Larazotide for Celiac Disease

Price target decreased to US$4.33

President recently bought US$53k worth of stock

President recently bought US$53k worth of stock

Independent Chairman recently bought US$100k worth of stock

Director Sandeep Laumas has left the company

9 Meters Biopharma, Inc. Announces Initiation of Phase 2 Vibrant Study of Vurolenatide for Short Bowel Syndrome

9 meters launches Phase 2 VIBRANT study of vurolenatide for short bowel syndrome

9 Meters Biopharma, Inc. Announces Publication in Journal of Clinical Investigation Describing Successful Use of Larazotide for Treating Multisystem Inflammatory Syndrome in Children Resulting from Covid-19 Infection

9 Meters drug effective in treating rare COVID-19 complication in children

9 Meters Biopharma, Inc. Receives USAN Approval to Use the Designated Nonproprietary Name Vurolenatide for Its Long-Acting GLP-1 Agonist for Short Bowel Syndrome

Forecast to breakeven in 2024

9 Meters Biopharma Hosting Key Opinion Leader Webinar on Short Bowel Syndrome and NM-002 Program Update

9 Meters Biopharma Inc Appoints Michael Rice as Board of Director

9 Meters Biopharma, Inc. Announces the Resignation of Nissim Darvish as Director

Independent Director has left the company

New 90-day high: US$1.50

New 90-day high: US$1.37

9 Meters Bio gains 5% on Adage Capital stake disclosure

9 Meters Biopharma slumps, continues evaluation of Larazotide for COVID-19 respiratory complications

9 Meters Biopharma, Inc. has completed a Follow-on Equity Offering in the amount of $30.000001 million.

9 Meters Bio launches equity offering

9 Meters Biopharma Announces Positive Preclinical Data for NM-102, a Gut Microbiome Modulator in an Immune Checkpoint Inhibitor Failure Model

New 90-day high: US$0.89

New 90-day high: US$0.85

Independent Chairman recently bought US$96k worth of stock

Independent Chairman recently bought US$56k worth of stock

New 90-day low - US$0.47

Innovate Biopharmaceuticals, Inc. (NasdaqCM:INNT) completed the acquisition of RDD Pharma, Ltd. from OrbiMed Israel Partners managed by OrbiMed Advisors, L.L.C. and others.

9 Meters Biopharma, Inc.(NasdaqCM:NMTR) dropped from Russell Microcap Index

Analyse der Geschäftsführervergütung

Geschäftsführer

Amtszeit

Vergütung

Vorstandsmitglieder

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter